by François Briand | May 30, 2023 | 2023
Physiogenex is a proud sponsor of the Hanson Wade 1st Type 2 diabetes & Obesity Therapeutics Summit to be held in Boston, May 30th – June 1st, 2023: On June 1st 9:20am, Dr. François Briand, our Director of Research and Business Development, will be...
by François Briand | May 11, 2023 | 2023
Physiogenex will be attending Biomed Israël 2023 annual meeting in Tel Aviv, May 16 – May 18 and will be hosted by Business France French HealthCare at booth #60. Our Director of Research and Business Development at Physiogenex, Dr. François Briand will be...
by François Briand | May 11, 2023 | 2023
Physiogenex, a leading preclinical contract research organization specialized in metabolic diseases and complications, and Vaiomer, a pioneer company in the field of microbiota, launch the TRANSBIOTIC project: a new research project to transplant mice with human fecal...
by François Briand | Apr 19, 2023 | 2023
Physiogenex and its subsidiary company Cardiomedex will be presenting a new diabetic NASH HFpEF hamster model at the Keystone Symposia on type 2 diabetes therapeutics in Palm Springs, CA, USA May 1-4, 2023. This unique preclinical model will be presented during the...
by François Briand | Mar 28, 2023 | 2023
Physiogenex, its subsidiary company Cardiomedex, and its partner CLEA Japan Inc., will be presenting their collaborative work at the ISN-World Congress of Nephrology, to be held March 30-April 2 in Bangkok, Thailand. Dr. François Briand, our Director of Research and...
by François Briand | Mar 15, 2023 | 2023
Physiogenex will be presenting its innovative obese NASH hamster model at the NAFLD/NASH Keystone Symposia, Banff, AB, Canada March 19-23, 2023. This unique preclinical model will be presented during the March 20th poster session from 7:30pm by Dr. François Briand,...
